1. Tuberculosis alters immune-metabolic pathways resulting in perturbed IL-1 responses
- Author
-
Nicole Bilek, Violaine Saint-André, Elisa Nemes, Stanley Kimbung Mbandi, Elizabeth Filander, Munyaradzi Musvosvi, Humphrey Mulenga, Matthew L. Albert, Alba Llibre, Vincent Rouilly, Hadn Africa, Céline Posseme, Simba Mabwe, Nikaïa Smith, Vincent Bondet, Thomas J. Scriba, Pierre Bost, Darragh Duffy, Bruno Charbit, Immunologie Translationnelle - Translational Immunology lab, Institut Pasteur [Paris] (IP), Datactix, University of Cape Town, Ecole Doctorale Complexité du Vivant (ED515), Sorbonne Université (SU), Cytometrie et Biomarqueurs – Cytometry and Biomarkers (UTechS CB), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Département de Biologie Computationnelle - Department of Computational Biology, Insitro [San Francisco], This study was funded by the Bill and Melinda Gates Foundation (OPP1114368 and OPP1204624), with additional support from the French Government’s Investissement d’Avenir Program, Laboratoire d’Excellence 'Milieu Intérieur' Grant ANR-10-LABX-69-01. AL was supported by the Fondation Recherche Médicale (SPF20170938617) and the European Commision (H2020-MSCA-IF 2018, 841729). NS was supported by an Institut Pasteur Roux Cantarini fellowship., We thank the UTechS CB of the Center for Translational Research, Institut Pasteur for supporting Nanostring analysis. DD thanks Immunoqure for provision of the mAbs under an MTA for the Simoa IFN-α assay. We are grateful to the study participants and the SATVI clinical and laboratory teams., ANR-10-LABX-0069,MILIEU INTERIEUR,GENETIC & ENVIRONMENTAL CONTROL OF IMMUNE PHENOTYPE VARIANCE: ESTABLISHING A PATH TOWARDS PERSONALIZED MEDICINE(2010), Institut Pasteur [Paris], and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Tuberculosis ,Immunology ,Disease ,Mycobacterium tuberculosis ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antigen ,Interleukin 1 (IL-1) ,Medicine ,Immunology and Allergy ,Interleukin 1 Receptor antagonist (IL-1ra) ,030304 developmental biology ,Systems immunology ,0303 health sciences ,Immunometabolism ,biology ,business.industry ,biology.organism_classification ,medicine.disease ,3. Good health ,Granzyme ,biology.protein ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Tumor necrosis factor alpha ,business ,030215 immunology - Abstract
SUMMARYTuberculosis (TB) remains a major public health problem with host-directed therapeutics offering potential as novel treatment strategies. However, their successful development still requires a comprehensive understanding of howMycobacterium tuberculosis(M.tb) infection impacts immune responses. To address this challenge, we applied standardised immunomonitoring tools to compare TB antigen, BCG and IL-1β induced immune responses between individuals with latentM.tbinfection (LTBI) and active TB disease, at diagnosis and after cure. This revealed distinct responses between TB and LTBI groups at transcriptomic, proteomic and metabolomic levels. At baseline, we identified pregnane steroids and the PPARγ pathway as new immune-metabolic drivers of elevated plasma IL-1ra in TB. We also observed dysregulated induced IL-1 responses after BCG stimulation in TB patients. Elevated IL-1 antagonist responses were explained by upstream differences in TNF responses, while for IL-1 agonists it was due to downstream differences in granzyme mediated cleavage. Finally, the immune response to IL-1β driven signalling was also dramatically perturbed in TB disease but was completely restored after successful antibiotic treatment. This systems immunology approach improves our knowledge of how immune responses are altered during TB disease, and may support design of improved diagnostic, prophylactic and therapeutic tools.
- Published
- 2022